Spontaneous regression of metastatic renal cell carcinoma

Snow, Ross; Schellhammer, Paul F.

doi:10.1016/0090-4295(82)90356-9

Cited by 101 publications

(44 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A similar case is reported by Kavoussi et al [17], other positive cases by Bloom [3]. Therefore, there is a big chance that the presence or lack of oestrogen or progesterone receptors may predict a response to anti-oestrogen or progesterone therapy [26].…”

Section: Discussionsupporting

confidence: 73%

“…Hcwexer, many authors ha~e proved that spontaneous regression can occur. The tumour with the second most reported spontaneous regressions is renal cell carcinoma (after malignant melanoma) [26]. Katz and Schapira [16] e,~en put renal cell carcinoma (RCC) in first place followed by neuroblastoma, melanoma and choriccarcircn~a, in decreasing order of frequency.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metastatic renal cell carcinoma (RCC): Spontaneous regression, long-term survival and late recurrence

Riese

Goldenberg

Allhoff

et al. 1991

International Urology and Nephrology

View full text Add to dashboard Cite

We report 4 cases of metastatic renal cell carcinoma (RCC) with long-term survival either following radical nephrectomy alone or in combination with radioor hormonal therapy.Two patients with lymph node metastases showed a long-term survival of 12 or more years following radical tumour nephrectomy (with lymphadenectomy) and radiotherapy. One of them exhibited a histologically proven tumour recurrence nearly 12 years after pIimary surgical treatment and died shortly later; the other one is still without any evidence of metastatic disease.Two other patients exhibited spontaneous regression of pulmonary metastases: one regression occurred after radical tumour nephrectomy alone, the other one after successful primary hormonal treatment and subsequent radical tumour nephrectomy.The following important aspects are emphasized: 1. Renal cell carcinoma is a very unpredictable tumour. Once the diagnosis of renal cell carcinoma is proved, a patient can never be considered cured.2. Although adjuvant palliative nephrectomy has produced contradictory results in several reports, radical tumour nephrectomy either alone or in combination with other adjuvant therapies such as radiotherapy, hormonal or immunological treatment, can be worthwhile. Cases with long-term survival and spontaneous regression of distant metastases are proof of this. Besides, if carefully selected, the mortality rate of different adjuvant therapies is not significantly higher in patients with metastatic disease than in patients without metastases.The world literature on this subject is reviewed.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 99%

Metastatic renal cell carcinoma (RCC): Spontaneous regression, long-term survival and late recurrence

Riese

Goldenberg

Allhoff

et al. 1991

International Urology and Nephrology

View full text Add to dashboard Cite

show abstract

“…It was shown that NPY can inhibit the growth of tumor cell lines under certain conditions 8 and stimulate it in others. 36 In this context, it is interesting that RCCs have long been con- sidered to undergo host defense based on the possibility of spontaneous tumor regression 37,38 and response to immune therapy.…”

Section: Discussionmentioning

confidence: 99%

Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas

Körner

Waser

Reubi

2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Numerous peptide receptors are overexpressed in human cancer, permitting in vivo tumor targeting. Among such receptors, those for the neurotransmitter neuropeptide Y (NPY) are overexpressed in various tumors. Since NPY can play a role in the kidney, NPY receptor expression and/or endogenous production of peptides of the NPY family (NPY, PYY, PP) were evaluated in 40 renal cell carcinomas (RCCs) and 18 nephroblastomas. NPY receptor protein expression was investigated by in vitro autoradiography using 125 I-labeled PYY in competition with NPY receptor subtype-selective analogs. NPY, PYY and PP production was assessed immunohistochemically. Fifty-six percent of RCCs expressed the Y1 receptor subtype in moderate density, and 80% of nephroblastomas expressed Y1 and Y2 subtypes in moderate to high density. Y1 was also highly expressed in intratumoral blood vessels. In selected cases, NPY was observed in nerve fibers in close association with intratumoral blood vessels and in the vicinity of tumor cells, while no PYY or PP was detected immunohistochemically in these sites. NPY receptors on renal tumor cells and tumor blood vessels may therefore be the molecular targets of endogenous NPY released by intratumoral nerve fibers. With regard to clinical applications, NPY receptors may act as in vivo targets for receptor-directed therapy of RCCs and nephroblastomas for which alternative therapeutic approaches are still required. ' 2005 Wiley-Liss, Inc.Key words: NPY receptor; renal cell carcinoma; nephroblastoma; receptor autoradiography Peptide hormone receptors are overexpressed in a wide variety of human tumors.1 Like other cell surface molecules, these receptors become increasingly important for clinical applications. In particular, they allow receptor-targeted tumor imaging and therapy with corresponding peptide hormone analogs. For instance, scintigraphy using the somatostatin analog Octreoscan is highly sensitive at detecting gastroenteropancreatic neuroendocrine tumors which express somatostatin receptors in high amounts.2,3 Moreover, targeted radiotherapy of these tumors with 90 Y-or 177 Lu-labeled somatostatin analogs is also promising. 4,5 Another peptide hormone receptor family with a potential future role in this field is the NPY receptor family. It belongs to the G protein-coupled receptor superfamily and comprises various subtypes. Subtypes Y1, Y2, Y4 and Y5 are expressed in humans. 6 They are present mainly in the central and peripheral nervous systems as well as other tissues, such as the cardiovascular system. Their physiologic ligands are the neurotransmitter NPY and the 2 hormones PYY and PP. Among many other sites, NPY has been localized to perivascular nerves in the human kidney. 7 NPY receptors may also play a role in human neoplasia. High incidence rates of subtypes Y1 and Y2 were found in tumors related to steroid hormone metabolism (adrenal cortical tumors, ovarian sex cord-stromal tumors, breast carcinomas), 8,9 in neuroendocrine tumors (pheochromocytomas and paragangliomas) 10

show abstract

“…Both pre-clinical and clinical data [11][12][13] suggest that these effects are immune mediated. 14,15 Despite these observations, both the tumor and its microenvironment seem to be able to evade the immune system in the majority of cases. Radiotherapy alone is probably unlikely to induce persistent antitumor immunity and a combination with synergistic immunomodulatory agents might be necessary to induce long-term clinical results, as suggested by promising preclinical and clinical data.…”

Section: Introductionmentioning

confidence: 99%